Standard & Poor’s announced today that it has commenced Factual Stock Report coverage on Northwest Biotherapeutics.

Northwest Biotherapeutics, Inc. (BB: NWBO), is a development-stage biotechnology company working in the US and Europe on immune therapies to generate and enhance immune system responses to treat cancer without toxic side effects. The Company's approach utilizes its expertise in the biology of dendritic cells (DC), which are the master cells of the human immune system. The researcher who discovered this critical role of dendritic cells was just awarded this year's Nobel Prize in medicine.

As recently presented in several New York financial conferences, the Company has clearance from the FDA to conduct clinical trials on more than half a dozen different cancers, including clearances for a late stage trial in GBM (Glioblastoma multiforme -- the most aggressive and lethal brain cancer), and clearance previously received for a Phase III trial in prostate cancer. NWBO's prior Phase I/II trials in GBM, prostate and ovarian cancers have consistently shown encouraging positive results.

When compared to other active immune therapy companies in the expanding cancer immune space, NWBO believes their DCVax technology is more effective, longer lasting, easier to administer, can be less costly, and can potentially apply to all patients with the target cancers, while certain other companies' treatments can only apply to a limited portion of the patient population and require screening of patients to determine which of them can be treated. In addition, NWBO has a deeper product pipeline, with multiple product lines and multiple target cancers already cleared for clinical trials by FDA. NWBO is unique in pursuing Europe in parallel with the US, for both its clinical trials and its manufacturing.

S&P Factual Stock Report coverage on Northwest Biotherapeutics, will also be accessible on an ongoing basis to the investment community by scores of buy-side institutions and sell-side firms that utilize S&P research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts. Please visit www.nwbio.com for additional information.

About Standard & Poor's Factual Stock Reports

This Standard & Poor’s service provides factual research coverage enabling information about Northwest Biotherapeutics, Inc and other securities to reach a wide investor audience of Buy and Sell-side investors, helping them understand a company’s fundamentals and business prospects. Currently profiling over 500 issuers, S&P Factual Stock Reports increase market awareness for issuers in the investment community with insightful commentary and key statistics/information. Updated weekly with the latest pricing, trading volume, and other data, the reports include recent developments, a financial review, key operating information, Industry and peer comparisons, institutional holdings analysis, Street Consensus and opinions, performance charts, business summary, fundamental data, and news. Because coverage of these reports is sponsored by the issuer, S&P does not offer investment opinions concerning the advisability of investing in these stocks.

Standard & Poor’s Factual Stock Reports are produced separately from any other analytic activity of Standard & Poor’s. Standard & Poor’s Factual Report research has no access to non-public information received by other units of Standard & Poor’s. Standard & Poor’s does not trade on its own account.

Note: All U.S. and Canadian Companies listed on a National Exchange (not covered by S&P’s STARS research) are eligible to obtain this coverage.

About Standard & Poor's

Standard & Poor's, a division of The McGraw-Hill Companies (NYSE: MHP), is the world's foremost provider of financial market intelligence, including independent credit ratings, indices, risk evaluation, investment research and data. With approximately 10,000 employees, including wholly owned affiliates, located in 23 countries, Standard & Poor's is an essential part of the world's financial infrastructure and has played a leading role for more than 140 years in providing investors with the independent benchmarks they need to feel more confident about their investment and financial decisions. For more information, visit http://www.standardandpoors.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50042398&lang=en

Copyright Business Wire 2010

If you liked this article you might like

Northwest Bio Receives SEC Subpoena and Other Awful Nuggets From New 10-K

Northwest Bio Receives SEC Subpoena and Other Awful Nuggets From New 10-K

Northwest Bio Executive Pleads Ignorance about Clinical Trial Halt, Stock Collapse

Northwest Bio Executive Pleads Ignorance about Clinical Trial Halt, Stock Collapse

Northwest Biotherapeutics agrees to pay bondholders $11 million, needs cash

Northwest Biotherapeutics agrees to pay bondholders $11 million, needs cash

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

Biotech School: How to Spot Hidden Danger Signs in Clinical Trial Data

Biotech School: How to Spot Hidden Danger Signs in Clinical Trial Data